Drug Profile

Anti-CD22 monoclonal antibody-toxin conjugate - Galileo Research/the University of Texas

Alternative Names: IMTOX 22 N97A; IMTOX-22; RFB4-N97A

Latest Information Update: 13 Feb 2014

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Royal Free and University College Medical School; University of Texas Southwestern Medical Center
Developer Galileo Research; National Cancer Institute (USA)
Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
Mechanism of Action Protein synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Feb 2014 No development reported - Phase-I for B-cell lymphoma in USA (Parenteral)
24 Nov 2010 Phase-I development is ongoing in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com